Company Overview
RenovoRx, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to developing targeted combination therapies designed to improve therapeutic outcomes for cancer patients undergoing treatment. The company's primary focus centers on its lead product candidate, which utilizes chemotherapy gemcitabine administered through a proprietary RenovoCath delivery system currently in Phase of development. This organization functions within the Healthcare sector, specifically the Biotechnology industry, where the primary objective involves advancing novel pharmaceutical compounds and delivery mechanisms to address unmet medical needs in oncology. The company maintains a market capitalization of $53.44M and generates annual revenue of $928,000 from a workforce consisting of 10 employees. These financial figures indicate that RenovoRx is a small-cap entity with a highly specialized operational footprint, reflecting the typical capital intensity and early-stage nature of biotechnology firms that prioritize research and development expenditures over immediate revenue generation.
Financial Health
The company reported revenue of $928,000 for the trailing twelve months, while simultaneously posting a net income of $-11,105,000 and an EBITDA figure listed as not available. The substantial disparity between the minimal revenue of $928,000 and the significant net loss of $-11,105,000 reveals a cost structure heavily weighted toward research, development, and operational expenses that far exceed current sales, a common characteristic of clinical-stage biopharmaceutical companies. Free cash flow stands at $-6,499,500, indicating that the company is burning cash to fund its operations and development pipeline rather than generating liquidity from its business activities. Regarding profitability metrics, the gross margin is reported at 67.8%, suggesting that the cost of goods sold is relatively low compared to revenue, whereas the operating margin is -1203.0% and the profit margin is 0.0%, highlighting severe operating inefficiencies or massive overhead costs relative to current sales volume. The balance sheet shows the company holds $10.04M in cash against $236,000 in debt, resulting in a debt-to-equity ratio of 2.92, which suggests a leveraged position where equity is diluted relative to liabilities despite the absolute value of debt being low. Liquidity is supported by a current ratio of 5.83, indicating that the company possesses ample short-term assets to cover its short-term obligations with a high degree of safety. Return on Equity is -146.6% and Return on Assets is -68.4%, metrics that reveal that management is currently utilizing shareholder and asset bases to generate negative returns, a typical phase for companies in the clinical development stage before product commercialization.
Valuation Assessment
The trailing P/E ratio is listed as not available due to the lack of positive net income, while the forward P/E is -4.19, implying that analysts or market participants are pricing in future earnings recovery or expecting a return to profitability. The price-to-book ratio stands at 5.14, indicating that the market values the company at a significant premium over its book value, likely reflecting the potential value of its intellectual property and clinical pipeline rather than current assets. Alternative valuation metrics such as the price-to-sales ratio of 57.58 and the EV/EBITDA ratio of not available suggest that investors are valuing the company based on revenue multiples, which is standard for pre-revenue or loss-making biotech firms where traditional earnings-based multiples are distorted. The stock has traded within a 52-week range with a high of $1.45 and a low of $0.70, placing the current price dynamics within a volatile band typical for small-cap biotechnology stocks. With a beta of 1.33, the stock exhibits price volatility that is higher than the broader market, meaning it tends to amplify market movements with greater intensity than large-cap equities.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as not available, preventing a direct comparison of growth rates between the two metrics, but the context of the company being in a clinical stage implies that earnings are currently negative while revenue is in early formation. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, as indicated by the 0.0% payout ratio and not available dividend yield, meaning all available capital is theoretically reinvested into growth initiatives rather than distributed to shareholders. This reinvestment strategy is necessary for the company to advance its clinical trials and develop its targeted combination therapies for cancer patients. The overall growth and income profile for RenovoRx, Inc. is characterized by a lack of current profitability and cash generation, relying instead on existing cash reserves and potential future financing to sustain operations until the commercialization of its lead product candidate.